Tuesday, October 13, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 2, 2026

China's Rare Earth Grip on the U.S. Military Is About to Break

View original at finance.yahoo.com
China's Rare Earth Grip on the U.S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • It isn't rare earths that are critical to national security, it's the 'rare processing' industry

    80% confidence
  • REalloys expects to become the largest producer of refined Dysprosium and Terbium outside of China

    80% confidence
  • 1% reliance on China is 100% reliance on China - if any single input comes from Beijing, entire operation is one phone call away from shutting down

    80% confidence
  • REalloys expects scaled production to reach 18,000 tonnes per year of heavy rare earth permanent magnets

    80% confidence
  • REalloys expects to be the only company with a fully operational, non-Chinese, mine-to-magnet supply chain when Pentagon deadline arrives

    80% confidence
  • REalloys expects to receive approximately 460 tonnes of defense-grade rare earth metals per year once Saskatchewan plant reaches full production

    80% confidence
  • Starting from zero, it would realistically take five to seven years to build what REalloys already has

    80% confidence
  • Concentrates are commodities, materials are commitments

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com
China's Rare Earth Grip on the U.S. Military Is About to Break — Source | Via News | Via News